Kornimate/medical-research-clean huggingface dataset:
integral management of healthcare problems related with drugs in polimedicated patients: medication code

Conditions: Drug Related Problems; Pharmaceutical Care

Summary: background: although drug- related problems (drps) in polimedicated patients are a major public health problem in western countries and many of them have been considered avoidable, secondary and primary prevention policies have not been systematized, beyond pharmaceutical care programs in certain settings and on specific patients. objectives: the main objective of this study is to evaluate the impact of implementing the medication code (cm) on patients who consult the emergency department for a drp (secondary prevention of drp). it is also intended to draw conclusions, based on the knowledge obtained in terms of drp that will allow the establishment of future actions to reduce its prevalence (primary prevention actions). method: a single-centre clinical trial is proposed in which adult patients will be selected to consult the hospital emergency department (ed) of the hospital de la santa creu i sant pau (hscsp) for a primary or secondary diagnosis of drp and will be randomised with a 1:1 distribution to be included in the medication code (intervention group) or to receive usual care (control group). the intervention will be evaluated in terms of health outcomes (ed consultations and hospital readmission).

a single-centre clinical trial is proposed in which adult patients will be selected to consult the hospital emergency department (ed) of the hospital de la santa creu i sant pau (hscsp) for a primary or secondary diagnosis of drp and will be randomised with a 1:1 distribution to be included in the medication code (intervention group) or to receive usual care (control group). the intervention will be evaluated in terms of health outcomes (ed consultations and hospital readmission).

Eligibility criteria:
inclusion criteria: * age \>= 18 years * drug related problems (drp) related to drugs from anatomical therapeutic chemical (atc) groups a, b and c exclusion criteria: * drp due to autolytic attempt or final phase of life. * denied informed consent

Keywords: secondary prevention pharmaceutical care drug related problems emergency department
an exploratory study of continuous theta burst stimulation (ctbs) based on fmri in the treatment of tic disorder

Conditions: Tic Disorders; Tourette Syndrome

Summary: continuous theta burst stimulation (ctbs) is a safe and effective device for gilles de la tourette's syndrome treatment. gpi is an agreed curative target of deep brain stimulation. gpi-based functional connectivity peak voxel in the sma can be the ctbs target.

tic disorder is a common neuropsychiatric disorder in children and adolescents. medication is not effective and has side effect. exploring new treatment methods is one of the research pathway of this disease.continuous theta burst stimulation (ctbs) is relatively safe and effective, and its efficacy in psychiatric diseases has been gradually recognized. however, the results of current researches of tic disorder treatment are varied, and the evaluation method is relatively single. this project intends to adopt fmri-guided stimulation target and navigated ctbs to intervene patients with tics and explore individualized ctbs treatment parameters of tics, including stimulation frequency, intensity, type, time and stimulation target. previous studies for deep brain stimulation reported that the medial globus pallidus (gpi) showed an obvious curative effect. and a deep brain area can be modulated indirectly by a superficial target via functional connectivity. therefore, the present study attempts to stimulate the superficial target in supplementary motor area (sma), lateral motor area (m1) which functionally connected with gpi or thalamus since the thalamus also a commonly reported abnormal brain area of tic. combined with clinical symptoms and neuroimaging, the therapeutic effect of ctbs in children with tic disorder was comprehensively evaluated in order to provide a new therapeutic method and a better therapeutic effect for the disease.

Eligibility criteria:
inclusion criteria: 1. meet the diagnostic criteria of chronic tic disorder or tourette syndrome; 2. yale global tic severity scale (ygtss) score is greater than 20; 3. the symptoms lasted more than 1 year, and the drug regimen was not adjusted within one month; 4. right-handedness; 5. age 6-20 years; 6. able to receive continuous theta burst stimulation (ctbs) therapy, participants and their guardians agree to receive treatment and observation. exclusion criteria: 1. age is under 6-year old; 2. can not tolerate mri or ctbs treatment; 3. adjust medication during treatment.

Keywords: continuous theta burst stimulation (ctbs) fmri
electroacupuncture for the treatment of functional constipation

Conditions: Functional Constipation

Summary: the purpose of this study is to investigate the effect of electroacupuncture on functional constipation.

this study will supply significant evidence for using acupuncture to treat functional constipation(fc), and will help us to identify whether it is a therapeutic effect rather than a placebo effect.

Eligibility criteria:
inclusion criteria: * functional constipation according to the roman ⅲ standard; * aged between 18 and 65 years old exclusion criteria: * unconsciousness, psychosis or can't express subjective symptoms; * pregnant women or women in lactation period; * serious diseases of the heart, liver, kidney, and others; * bleeding disorders.

Keywords: acupuncture electro-acupuncture
av junction ablation or optimal medical treatment in patients with cardiac resynchronization therapy and permanent atrial fibrillation

Conditions: Recurrent Atrial Fibrillation; Persistent Atrial Fibrillation

Summary: a study comparing atrioventricular junction ablation (avja) versus continued optimum medical rate control in patients with cardiac resynchronization therapy (crt) and atrial fibrillation (af) with suboptimal heart rate control on optimum medication.

patients fulfilling the enrolment criteria will be randomly (randomization with variable blocks of 4, 6, and 8 patients) allocated to intervention and control groups in a 1:1 ratio. avja will be done in patients belonging to the intervention group without undue delay after the randomization. the procedure will be repeated in case of recovery of av nodal conduction during the trial. crt device will be programmed to a base rate of 70 bpm, hysteresis switched off, and rate response functions activated unless not tolerated by the patient. the triggered mode will be encouraged. all patients will be regularly followed in outpatient clinics. cross-over to the avja study arm will be considered and performed at any time during the trial at the discretion of the operators. this may particularly concern patients with clinical deterioration in terms of functional status, quality of life, systolic left ventricular function, and/or repeated hospitalization, and in whom biventricular pacing (bivp%) \<\<100% could be suspected as a significant underlying factor.

Eligibility criteria:
inclusion criteria: * treatment with crt using either a biventricular pacemaker/defibrillator or conduction system pacemaker (\>6 months) * diagnosis of af and classified as: permanent af or recurrent persistent af, requiring emergency visits and/or hospitalizations (at least one in recent year) * optimized hf medical treatment and rate control medication * bivp% + ventricular premature complex (vpc%) \ 85% during the minimum period of 1 month while already on optimum medical therapy (applicable only for patients with permanent af) * age \>18 and \<85 years * signed informed consent exclusion criteria: * myocardial infarction (mi) or coronary artery bypass graft (cabg) \<3 months * technical failure of the crt system * intentional preference for spontaneous av conduction * expected survival \<1 year * other significant comorbidities and/or conditions that interfere with the proper conduction of the trial * dementia as assessed by mini-mental test (\<23 points)

Keywords: atrial fibrillation atrioventricular junction ablation biventricular pacing heart rate control cardiac resynchronization therapy
cohort of patients naive of antiretroviral treatment at enrollment

Conditions: HIV Infection

Summary: the purpose of this study is to evaluate the short, medium and long-term prognosis for newly diagnosed hiv patients.

the purpose of this study is to evaluate the short, medium and long-term prognosis for newly diagnosed hiv patients. this study aims to precise the impact of hiv infection treatment on morbidity and mortality, the factors related to treatment response, clinical and biological complications, their consequences, especially lipodystrophy and metabolic abnormalities, associated factors especially genetic, aspects linked to aging. in addition, the study describes the evolution of patients living conditions and behaviors remotely from their screening, particularly related to sexuality, reproduction, and health inequalities and to study the long-term treatment adherence. one third of the patients were included in the metabolic disorders module. this module includes additional biological and imaging explorations.

Eligibility criteria:
inclusion criteria: * patients infected with hiv-1, with a recent diagnosis (\<1 year before enrollment) * untreated at the time of enrollment, * aged 15 or more * agreeing to participate in the cohort. exclusion criteria: * under protection(saving) of justice
post-stroke sensory reweighting on walking and balance outcomes

Conditions: Ischemic Stroke

Summary: the primary objective of this proof-of-concept study is to longitudinally track the development of post-stroke sensory reweighting (psr), identify associated structural neuroanatomical correlates, and investigate their relationship to walking and fall outcomes.

post-stroke imbalance and walking impairment is a function of diminished sensorimotor integration, motor, and postural control. it impacts over 75% of stroke survivors, and remain a rising cause of falls, fractures, and death in the united states. the associated fear of falling often leads to a downward spiral of health, characterized by reduced walking performance, caregiver dependency, social isolation, and the development of secondary post-stroke medical complications. although spontaneous biological recovery and intensive clinical rehabilitation may improve balance and walking ability, the extent of recovery is often limited after the first 6-months of stroke (chronic phase). furthermore, currently available clinical measures such as the berg balance scale and timed-up-and-go lack the specificity and granularity needed to foster the development of individualized and targeted neurorehabilitation interventions. in addition, non-invasive neurostimulation strategies lack specificity due to limited understanding of the most appropriate neuroanatomical targets for optimizing sensorimotor integration. hence there is an urgent need to identify reliable physiologic and neuroanatomic correlates in the earlier stages of recovery (\<6 months), to enable timely and targeted rehabilitation interventions.

Eligibility criteria:
inclusion criteria: 1. first ever clinical stroke 2. stroke due to ischemia 3. age 18 years or older 4. ability to consent by patient (not surrogate), any time prior to acute hospital discharge exclusion criteria: 1. pre-stroke dependence (modified rankin scale score of 3 or more) 2. isolated brainstem or cerebellar stroke 3. bilateral acute strokes 4. co-enrollment in a trial of an intervention through six-month follow-up 5. inability to maintain follow-up with study procedures through six-month follow-up 6. contraindication to non-contrast mri 7. low likelihood of survival beyond the acute hospitalization, such as malignant cerebral edema 8. pre-existing co-morbid conditions that significantly affects vision, somatosensory function, vestibular system, orthostasis, coordination or mobility 9. post stroke mrs\>4 or discharge to hospice
fractional laser assisted steroid therapy vs intralesional steroids in the treatment of keloids

Conditions: Keloid

Summary: the purpose of this study is to compare the effects of fractional carbon dioxide (co2) laser therapy immediately followed by intralesional steroid therapy against intralesional steroid therapy alone for the treatment of keloids.

intralesional corticosteroids remain the gold standard treatment for keloids. however, more effective therapies are desperately desired. ablative fractional laser (afl) treatment facilitates delivery of intralesional steroid more deeply and uniformly into the skin by creating vertical channels. recent studies have showed that fractional laser assisted steroid therapy can be effective in the treatment of keloids. however the studies are lacking in comparing this treatment modality to the gold standard of intralesional steroids.

Eligibility criteria:
inclusion criteria: * male or female older than 17 at the screening visit; * the subject is healthy, as determined by the investigator based on a medical evaluation including medical history; * the subject has at least two keloids of comparative size and texture located on the same general anatomic location (trunk or back); * the subject is willing and able to comply with the requirements of the protocol. in particular, subject must adhere to the visits schedule and concomitant therapy. the subject is willing to comply with the 4 week washout period; * the subject has understood and signed an informed consent form approved by the institutional review board (irb) prior to any investigational procedure exclusion criteria: any subject who is meeting one or more of the following exclusion criteria at the screening visit and/or at the baseline visit will not be included in this study: * the subject has an underlying known disease, a surgical or medical condition that in the opinion of the investigator might put the subject at risk * the subject is pregnant or breastfeeding at the time of enrollment or is planning to become pregnant at any point during the study period * the subject has a past history of coagulopathy * the subject has an underlying dermatological disease that in the opinion of the investigator could interfere with the study evaluations * the subject has used prohibited topical or systemic treatments without sufficient protocol-defined wash-out period prior to baseline (checked at screening and baseline) or is unwilling to refrain from use during the study * the subject is treated with anticoagulants or antiplatelet therapies * the subject has a known allergy or sensitivity to any local anesthetic drug (e.g. emla or tetracaine 7%/lidocaine 23%) or a local antiseptic planned to be used for the laser. * the subject is in an exclusion period from a previous study or is participating in another clinical trial * the subject is an adult under guardianship or is hospitalized in a public or private institution, or is deprived of freedom * the subject is unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function
study of bgb-a317 in participants with previously treated unresectable hcc

Conditions: Hepatocellular Carcinoma (HCC)

Summary: this study investigated the efficacy, safety, and pharmacokinetics of the anti-pd-1 monoclonal antibody bgb-a317 in participants with previously treated hepatocellular unresectable carcinoma.


Eligibility criteria:
key inclusion criteria: 1. histologically confirmed hcc 2. participants with barcelona clinic liver cancer (bclc) stage c, or bclc stage b not amenable to locoregional therapy or relapsed after locoregional therapy, and not amenable to a curative treatment approach 3. has received at least 1 line of systemic therapy for unresectable hcc 4. has at least 1 measurable lesion as defined per recist v1.1 5. child-pugh score a 6. easter cooperative oncology group (ecog) performance status ≤ 1 7. adequate organ function key exclusion criteria: 1. known fibrolamellar hcc, sarcomatoid hcc, or mixed cholangiocarcinoma and hcc histology 2. prior therapies targeting pd-1 or pd-l1 3. has known brain or leptomeningeal metastasis 4. tumor thrombus involving main trunk of portal vein or inferior vena cava 5. loco-regional therapy to the liver within 4 weeks before enrollment 6. medical history of interstitial lung disease, non-infectious pneumonitis or uncontrolled systemic diseases, including diabetes, hypertension, pulmonary fibrosis, or acute lung diseases 7. has received: 1. within 28 days or 5 half-lives (whichever is shorter) of the first study drug administration: any chemotherapy, immunotherapy (eg, interleukin, interferon, thymoxin) or any investigational therapies 2. within 14 days of the first study drug administration: sorafenib, regorafenib, or any chinese herbal medicine or chinese patent medicines used to control cancer 8. active autoimmune diseases or history of autoimmune diseases that may relapse 9. participant with any condition requiring systemic treatment with either corticosteroids (\> 10 mg daily of prednisone or equivalent) or other immunosuppressive medication within 14 days before study drug administration note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: advanced liver cancer rationale-208
a phase i/ii clinical study of nystatin i.v. (intravenous) in patients with hiv infection.

Conditions: HIV Infections

Summary: to evaluate the clinical toxicity, safety, and maximum tolerated dose (mtd) of intravenous nystatin in patients with hiv infection. to evaluate the potential anti-hiv activity and clinical pharmacology of intravenous nystatin.

cohorts of three patients each are treated at escalating doses of intravenous nystatin, administered every other day, until the mtd is reached. each cohort is observed for toxicity for at least 2 weeks before escalation in subsequent patient cohorts is initiated.

Eligibility criteria:
inclusion criteria concurrent medication: required: * aerosolized pentamidine (300 mg once a month) for pcp prophylaxis in patients with cd4 count \ 200 cells/mm3 who are already on aerosolized pentamidine may continue such therapy at the discretion of the investigator.) allowed: * prophylaxis against mycobacterium avium complex in patients with cd4 count \<= 100 cells/mm3. concurrent treatment: allowed: * local treatment for kaposi's sarcoma lesions with less than 25 percent increase in measurable disease. patients must have: * hiv antibody positivity. * absolute cd4 count \< 500 cells/mm3 on two determinations within 15 days prior to study entry. * at least 6 months of prior zidovudine (azt) therapy. * no active opportunistic infection requiring ongoing therapy. * normal neurologic status by standard assessment. * life expectancy of at least 6 months. exclusion criteria co-existing condition: patients with the following symptoms and conditions are excluded: * neoplasm other than basal cell carcinoma of the skin or stable untreated hiv-related kaposi's sarcoma (provided there is no progression in the kaposi's sarcoma beyond 25 percent of measurable disease). * clinically significant cardiac disease. * known hypersensitivity to polyene antibiotics. patients with the following prior conditions are excluded: * history of myocardial infarction or arrhythmias. prior medication: excluded within 2 weeks prior to study entry: * antiretroviral agents or interferons. * biological response modifiers. * corticosteroids. * cytotoxic chemotherapeutic agents. * drugs that can cause neutropenia or significant nephrotoxicity. * rifampin or rifampin derivatives. * systemic anti-infectives. prior treatment: excluded within 2 weeks prior to study entry: * radiation therapy. active drug or alcohol abuse.

Keywords: nystatin acquired immunodeficiency syndrome aids-related complex
propranolol for treatment of cocaine addiction - 2

Conditions: Cocaine-Related Disorders

Summary: the purpose of this study is to evaluate the safety and efficacy of propanolol in the early treatment of cocaine dependence.


Eligibility criteria:
please contact site for information.

Keywords: cocaine
a randomized study evaluating steroid hormone levels, safety and tolerability of gw870086x in healthy volunteers

Conditions: Asthma

Summary: gw870086x is a novel inhaled steroid that has an improved safety profile over other steroids but is also less potent. this study will look at higher doses to confirm the improved safety profile.

a randomized, double-blind, placebo-controlled, dose ascending, 3-cohort parallel group study to measure the systemic cortisol profile and evaluate the safety, tolerability and pharmacokinetics of gw870086x, administered as single doses (12mg and 15mg),and repeat doses over 3 days (6mg, 12mg and 15mg) in healthy male subjects.

Eligibility criteria:
inclusion criteria: * healthy male subjects * liver function tests normal * 18 - 45 years old * non smoker * can provide written informed consent * available to complete the whole trial * can use the inhalation device correctly * able to read, understand and write english exclusion criteria: * deemed suitable healthy subject * history to sensitivity to the study medication * any history of breathing problems in adult life * participated in another trial within 30 days or 5 half-lives of the new chemical entity * exposed to more than 4 new chemical entities within 12 months * donated \>500 ml blood within 2 months of screening * haemoglobin level \< 13g/dl * use of prescription or non-prescription drugs within 7 days of first dose * taking drugs that significantly inhibit cytochrome p450 subfamily enzyme cyp3a4 * drinks more than 4 units a day or 28 units a week * cannot use diskhaler device correctly * positive hepb, hepc within 3 months of screening * positive hiv test * positive pre study drug/alcohol screen * significant cardiac conduction abnormalities * risk of non-compliance

Keywords: gw870086x, inhaled, asthma, cortisol, pharmacokinetics, osteocalcin
role of dopamine transporter in glucose control

Conditions: Obesity

Summary: healthy subjects will be enrolled in this study. each subject will be scanned twice with f18-fp-cit pet which is commercially available. f18-fp-cit reflects dopamine transporter availability of striatum. before each pet scan, subject will be injected either glucose or normal saline. therefore, pet scan will reflect the changes of dopamine transporter availability after the injection of glucose.


Eligibility criteria:
inclusion criteria: * healthy subjects exclusion criteria: * known neurologic disorder * known drug addiction * known endocrine disorder